CLVT Q2 2026 Earnings Call Summary

Clarivate (CLVT) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: Q2 revenue was $587 million, with first-half revenue nearing $1.2 billion.
Net Loss: Reported a net loss of $269 million, primarily due to a non-cash impairment charge related to the divestiture of the Life Sciences & Healthcare (LS&H) segment.
Adjusted EPS: Increased to $0.19 in Q2, up from the prior year, contributing to a first-half adjusted EPS of $0.38 (19% increase YoY).
Organic ACV Growth: Improved to 1.5%, with Academia & Government (A&G) and Life Sciences & Healthcare segments each showing 2% growth. The Intellectual Property (IP) segment remained flat.
Adjusted EBITDA Margin: Expanded to over 42%, with disciplined cost management mitigating revenue declines.

2. Strategic Updates and Business Highlights

AI Innovation: Launched two new AI products—Nexus Connect and IP-1—aimed at enhancing research and IP workflows.
Divestiture of LS&H Segment: Agreement to sell LS&H to Altaris, expected to close by year-end, which will improve the company's focus on subscription-based revenue and enhance financial flexibility.
Subscription Model Shift: Continued transition from transactional to recurring revenue, with a pro forma recurring revenue mix expected to increase from 89% to approximately 92% post-divestiture.
Leadership Changes: Michael Easton appointed as CFO, succeeding Jonathan Collins, who has played a key role in the company's financial strategy.

3. Forward Guidance and Outlook

Full-Year Financial Guidance:
- Revenue expected just below the midpoint of the range at $2.35 billion.
- Organic annual contract value growth anticipated in the lower half of the range, with A&G approaching 3% growth and IP expected to return to growth by year-end.
- Adjusted EBITDA projected to remain over $1 billion, with margins near 43%.
- Free cash flow expected at the low end of the range due to transaction costs from the LS&H divestiture.

4. Bad News, Challenges, or Points of Concern

Transactional Revenue Declines: Organic revenues declined by $9 million, with specific headwinds noted in the Life Sciences business, attributed to a shift towards subscription models and industry factors.
Market Conditions: The company acknowledged that transactional revenue can be lumpy and subject to external pressures, which may impact future performance.
Impairment Charges: The significant net loss in Q2 was driven by a non-cash impairment charge, raising concerns about the financial impact of divestitures.

5. Notable Q&A Insights

Renewal Timing: Management indicated that Q2 ACV growth was affected by timing around renewals, but they do not expect elongation of renewal cycles to persist.
Client Migration: There is a strategic focus on migrating transactional business to subscription models, with ongoing efforts to improve retention and new sales.
AI Product Integration: The company is optimistic about embedding AI capabilities into existing workflows, which is expected to drive new revenue streams.
Market Validation: Recent awards for AI products like RiskMark highlight the company’s competitive positioning and innovation in the IP sector.

Overall, Clarivate is focused on accelerating organic growth through strategic divestitures, AI innovation, and a shift towards a subscription-based revenue model, while managing challenges related to transactional revenue and market conditions.

CLVT — Clarivate Plc